ArticleOncoimmunology
T cells specific for a TAP-independent self-peptide remain naïve in tumor-bearing mice and are fully exploitable for therapy.
Article in Oncoimmunology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 25 citations in OpenAlex.
- TEIPP-vaccination in checkpoint-resistant non-small cell lung cancer: a first-in-human phase I/II dose-escalation study.Nature communications · 2025Trial
- Messing with Signal 1: How Perturbed MHC Class I Antigen Presentation Contributes to Cancer.Cells · 2026Review
- Vaccination Against Pathogens Targeting Cell-Derived Cryptic Antigens.The Journal of infectious diseases · 2026Article
- Pipe dream to pipeline: Journey of cancer vaccines and the road ahead.Cell reports. Medicine · 2026Review
- Article
- Article
- HLA-E/Frontiers in immunology · 2024Article
- Multimodal immunogenomic biomarker analysis of tumors from pediatric patients enrolled to a phase 1-2 study of single-agent atezolizumab.Nature cancer · 2023Article
- Neoantigens: promising targets for cancer therapy.Signal transduction and targeted therapy · 2023Review
- Antigen presentation by MHC-E: a putative target for vaccination?Trends in immunology · 2022Review
- Cross-presentation of a TAP-independent signal peptide induces CD8 T immunity to escaped cancers but necessitates anchor replacement.Cancer immunology, immunotherapy : CII · 2022Article
- Aptamers: Cutting edge of cancer therapies.Molecular therapy : the journal of the American Society of Gene Therapy · 2021Review
- Investigating T Cell Immunity in Cancer: Achievements and Prospects.International journal of molecular sciences · 2021Review
- Healthy cells functionally present TAP-independent SSR1 peptides: implications for selection of clinically relevant antigens.iScience · 2021Article
- Review
- Future Challenges in Cancer Resistance to Immunotherapy.Cancers · 2020Review
- Tumor-targeted silencing of the peptide transporter TAP induces potent antitumor immunity.Nature communications · 2019Article
- Alternative tumour-specific antigens.Nature reviews. Cancer · 2019Review
- Refusing to TAP out: 16 new human TEIPPs identified.The Journal of experimental medicine · 2018Article
- Identification of non-mutated neoantigens presented by TAP-deficient tumors.The Journal of experimental medicine · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancers frequently evade immune-recognition by lowering peptide:MHC-I complexes on their cell surface. Limited peptide supply due to TAP-deficiency results in such MHC-I
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.